On This Day in Health: July 28, 1925
Baruch Samuel Blumberg was born in New York City on July 28, 1925. Trained as a physician, biochemist, and geneticist, he pursued a question that initially seemed far removed from vaccine development: why blood proteins vary among populations. During research involving samples collected around the world, Blumberg and colleagues identified an unusual antigen in the blood of an Aboriginal Australian person. The finding became known as the Australia antigen. Further work connected it to infectious hepatitis and ultimately to the surface antigen of the hepatitis B virus, revealing a cause of serious liver disease that had often spread silently.
The discovery changed blood safety and infectious disease research. Hepatitis B can pass through blood and other body fluids, from mother to child around birth, and through sexual contact or contaminated equipment. Many infected adults recover, but chronic infection can produce cirrhosis and liver cancer years later. Identifying a viral marker made it possible to screen donated blood and diagnose infection more accurately. It also showed that people without obvious symptoms could carry and transmit the virus. Blumberg's population research, laboratory investigation, and clinical interpretation joined epidemiology with molecular evidence, turning an unexpected protein signal into a practical public health tool.
Blumberg and collaborators then used hepatitis B surface antigen as the basis for an unusual vaccine derived from purified particles in the blood of carriers. Rigorous processing removed infectious material while preserving an immune target. That first generation vaccine demonstrated that protection could grow directly from understanding a viral component. Recombinant vaccines later replaced plasma-derived production and became part of routine childhood immunization in many countries. In 1976, Blumberg shared the Nobel Prize in Physiology or Medicine with D. Carleton Gajdusek for discoveries concerning new mechanisms in the origin and spread of infectious diseases. The award recognized work that connected basic research to prevention.
The World Health Organization marks World Hepatitis Day each July 28 because it is Blumberg's birthday. The observance links his scientific legacy to unfinished global work: expanding vaccination, preventing transmission at birth, increasing testing, treating chronic hepatitis, and reducing liver cancer. Hepatitis B vaccination is now a powerful form of cancer prevention, yet millions of people live with chronic infection, many without knowing it. Blumberg's career illustrates how curiosity about human variation can uncover a pathogen and produce tools with worldwide consequences. His birthday therefore commemorates both a scientist and the continuing public health effort made possible by his discoveries.
Blumberg studied inherited differences in blood proteins and identified the Australia antigen while comparing samples collected from diverse populations.
By the late 1960s, research linked the antigen to hepatitis B, enabling better diagnosis and screening of blood donations for a virus often carried without symptoms.
The first hepatitis B vaccine used purified surface-antigen particles from carrier plasma, an innovative approach that demanded stringent processing and safety controls.
Later recombinant vaccines avoided human plasma and supported broader immunization, including infant vaccination and prevention of mother-to-child transmission.
Hepatitis B vaccination prevents chronic liver disease and reduces the risk of liver cancer, making it one of the clearest links between vaccination and cancer prevention.
WHO chose July 28 for World Hepatitis Day to honor Blumberg while focusing attention on persistent gaps in vaccination, diagnosis, treatment, and equitable access.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.